Translating Advanced Cancer Research into Personalized, Passionate Treatment.
John Wayne Cancer Institute at Providence Saint John’s Health Center is a cancer research institute dedicated to the understanding, diagnosis, and innovative treatment of cancer in order to eliminate patient suffering and prolong survival.Read More
Steven O’Day, MD, Executive Director of the John Wayne Cancer Institute & Director of Providence Los Angeles Regional Research
Dr. O’Day is world-renowned in the field of medical oncology and his leadership capabilities make him the ideal person to lead the cancer and research efforts on our campus and in our region.
Cancer Innovation Newsletter
The world class cancer clinicians and translational scientists at the John Wayne Cancer Institute at Providence Saint John’s Health Center in Santa Monica, CA, work collaboratively to advance patient care. Our patients have access to the latest treatments and cutting edge new drug clinical trials. We are at the forefront of transforming discoveries leading to advancements in cancer medicine and patient survival.
We invite you to download a copy of Cancer Innovation, the quarterly newsletter of the John Wayne Cancer Institute, created to bring you the latest news and compelling stories from our cancer departments, highlighting our innovative work, nurturing care and groundbreaking research.Read the Summer 2020 Issue
Clinical trials have always been an important part of John Wayne Cancer Institute. Our institute led the trials that established sentinel lymph node biopsy as the standard of care for melanoma and breast care and pioneered immunotherapy as treatment for melanoma. Today, our patients continue to have access to the latest treatments and trials. We are at the forefront of studying the biology of cancer as well as expanding treatment for those suffering world-wide.Learn More
Attracting Patients from Around the World
As international leaders in cancer care, the John Wayne Cancer Institute attracts patients from all over the country and around the world. Seeing such a large number of patients, our team of experts bring a high level of experience to every aspect of your treatment. We’re with you from diagnosis through cure and have a team approach for better outcomes.Meet our Experts
Complex Surgical Oncology Fellowship
With a longstanding history of excellence in multidisciplinary cancer care and education, the John Wayne Cancer Institute continues to be a leader in training the next generation of leaders in the field of surgical oncology.Learn more about this fellowship
Urologic Oncology Fellowship
The JWCI provides world class, multidisciplinary training in genitourinary malignancies and urologic oncology research with innovative and cutting edge technology.Learn more about this fellowship
This training program focuses on endonasal endoscopic and keyhole surgical approaches, neuro-endoscopy, pituitary tumor management and multimodality neuro-oncology treatments.Learn more about this fellowship
Postdoctoral Lab-Based Translational Molecular Medicine Fellowship
As pioneers in translational studies on “liquid biopsies” involving circulating tumor cells in multiple types of solid tumors, the fellowship program also consists of studying epigenetic mechanisms regulating solid tumor as well as pharmacogenomics and immunogenomic based prediction of response to therapy.Learn more about this fellowship
Latest News & Events
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Przemyslaw W. Twardowski, M.D., and his colleagues, have published a new study in the New England Journal of Medicine, which demonstrates significant benefit of therapy with olaparib (PARP inhibitor) in patients with advanced prostate cancer who harbor certain mutations of DNA repair system and who failed standard treatments. Based on the results of that study on 5/19/2020 Food and Drug Administration (FDA) granted approval of olaparib, providing a valuable treatment option for about 25% of patients with advanced prostate cancer with certain mutations of DNA repair. These mutations can be detected by performing an analysis of a patient’s cancer specimen and sometimes also on a specialized blood test.
Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease
The Drug Discovery and Nanomedicine Laboratory (Yenugonda V and Waters A), along with Kesari S, and Allnutt AB, presents a review article in ACS Chemical Neuroscience highlighting the importance of Cdk5 activity and function in the brain and demonstrates how deregulation of Cdk5 can contribute to the development of neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.
ANG1005, a Brain Penetrating Peptide-Drug Conjugate, Shows Activity in Patients With Breast Cancer With Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
The department of Translational Neurosciences & Neurotherapeutics studied ANG1005, a novel taxane derivative, which consists of 3 paclitaxel molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via LRP1 transport system. Read the publication to learn the results.